Galapagos/$GLPG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Ticker
$GLPG
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
704
Website
Galapagos Metrics
BasicAdvanced
$2.2B
-
-$3.02
-0.06
-
Price and volume
Market cap
$2.2B
Beta
-0.06
52-week high
$33.10
52-week low
$22.59
Average daily volume
261K
Financial strength
Current ratio
7.945
Quick ratio
7.736
Long term debt to equity
0.283
Total debt to equity
0.395
Interest coverage (TTM)
-217.59%
Profitability
EBITDA (TTM)
-324.253
Gross margin (TTM)
45.46%
Net profit margin (TTM)
-58.83%
Operating margin (TTM)
-108.49%
Effective tax rate (TTM)
1.67%
Revenue per employee (TTM)
$481,180
Management effectiveness
Return on assets (TTM)
-4.66%
Return on equity (TTM)
-6.36%
Valuation
Price to revenue (TTM)
6.386
Price to book
0.67
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-5.8
Free cash flow yield (TTM)
-17.24%
Free cash flow per share (TTM)
-565.14%
Growth
Revenue change (TTM)
18.31%
Earnings per share change (TTM)
-160.73%
3-year revenue growth (CAGR)
-17.18%
10-year revenue growth (CAGR)
12.66%
3-year earnings per share growth (CAGR)
10.36%
10-year earnings per share growth (CAGR)
24.05%
Bulls say / Bears say
Galapagos' strategic decision to spin off its innovative medicines business by mid-2025 aims to provide clearer investment prospects, potentially enhancing shareholder value. (reuters.com)
The company's collaboration with Adaptimmune to develop TCR T-cell therapy candidate uza-cel for head & neck cancer could lead to significant advancements in oncology treatments. (newsfilecorp.com)
Galapagos' partnership with BridGene Biosciences to develop a selective oral SMARCA2 PROTAC for precision oncology demonstrates its commitment to innovative cancer therapies. (stocktitan.net)
StockNews.com downgraded Galapagos to a 'sell' rating, reflecting concerns about the company's future performance. (americanbankingnews.com)
Morgan Stanley lowered its rating on Galapagos from 'equal weight' to 'underweight' and reduced the target price from $31.00 to $22.00, indicating potential downside risk. (defenseworld.net)
The planned reorganization is expected to lead to the reduction of around 300 positions in Europe, or around 40% of the group's workforce, raising concerns about operational stability. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of $2.2B as of July 24, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of July 24, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of July 24, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.